Valion Bio (VBIO)
NASDAQ:VBIO
Want to see VBIO full AI Analyst Report?
Total Valuation
Valion Bio has a market cap or net worth of $1.92M. The enterprise value is $51.51M.
Market Cap$1.92M
Enterprise Value$51.51M
Share Statistics
Valion Bio has 3,200,824 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,200,824
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Valion Bio’s return on equity (ROE) is -0.64 and return on invested capital (ROIC) is -40.29%.
Return on Equity (ROE)-0.64
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-40.29%
Return on Capital Employed (ROCE)-0.41
Revenue Per Employee0.00
Profits Per Employee-293.62K
Employee Count3
Asset Turnover0.08
Inventory Turnover3.02
Valuation Ratios
The current PE Ratio of Valion Bio is 3.0. Valion Bio’s PEG ratio is -0.73.
PE Ratio3.0
PS Ratio197.61
PB Ratio17.36
Price to Fair Value17.36
Price to FCF-41.06
Price to Operating Cash Flow-86.15
PEG Ratio-0.73
Income Statement
In the last 12 months, Valion Bio had revenue of 0.00 and earned -880.85K in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit0.00
Operating Income-2.34M
Pretax Income-880.85K
Net Income-880.85K
EBITDA-880.85K
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -17.23K and capital expenditures 0.00, giving a free cash flow of -17.23K billion.
Operating Cash Flow-17.23K
Free Cash Flow-17.23K
Free Cash Flow per Share>-0.01
Dividends & Yields
Valion Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change-84.64%
50-Day Moving Average0.95
200-Day Moving Average1.66
Relative Strength Index (RSI)35.15
Average Volume (3m)99.84K
Important Dates
Valion Bio upcoming earnings date is Aug 17, 2026, Before Open (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Valion Bio as a current ratio of 11.72, with Debt / Equity ratio of 8.83%
Current Ratio11.72
Quick Ratio11.37
Debt to Market Cap0.00
Net Debt to EBITDA1.85
Interest Coverage Ratio-3.09
Taxes
In the past 12 months, Valion Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate>-0.01
Enterprise Valuation
Valion Bio EV to EBITDA ratio is -32.82, with an EV/FCF ratio of -38.87.
EV to Sales187.09
EV to EBITDA-32.82
EV to Free Cash Flow-38.87
EV to Operating Cash Flow-38.87
Balance Sheet
Valion Bio has $1.28M in cash and marketable securities with $500.00K in debt, giving a net cash position of $783.12K billion.
Cash & Marketable Securities$1.28M
Total Debt$500.00K
Net Cash$783.12K
Net Cash Per Share$0.24
Tangible Book Value Per Share$379.94
Margins
Gross margin is 25.75%, with operating margin of -483.02%, and net profit margin of -728.47%.
Gross Margin25.75%
Operating Margin-483.02%
Pretax Margin-728.39%
Net Profit Margin-728.47%
EBITDA Margin-570.07%
EBIT Margin-572.13%
Analyst Forecast
The average price target for Valion Bio is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-49.63%
EPS Growth Forecast82.22%